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Introduction
Human parvovirus B19 (B19V) is a common human pathogen 
that causes a variety of diseases with outcomes ranging from 
asymptomatic to severe symptoms, especially in immunocompro-
mised patients. The majority of these are asymptomatic or mild 
childhood infections. However, other clinical outcomes may occur, 
e.g., erythema infectiosum in children, transient aplastic crisis, 
chronic pure red blood cell (RBC) aplasia, prolonged joint pain in 
elderly individuals, pregnancy complications (foetal hydrops or 
spontaneous abortion) as well as severe prolonged anaemia in im-
munocompromised haematological patients [1, 2].
B19V is mainly transmitted through the respiratory route; how-
ever, vertical transmission from mother to foetus as well as through 
blood and blood products has been reported. B19V is also a trans-
fusion-transmitted agent because of the incomplete clearance of 
the virus after an acute infection, an extremely high viraemia in 
acutely infected individuals and the well-known resistance of the 
virus to many inactivation processes used during the manufactur-
ing of blood-derived plasma derivatives and labile blood products 
[2–6]. B19V viraemia occurs approximately 1 week after primary 
infection and persists at high titres of up to 1014 viral particles/ml 
in plasma for approximately 5 days [2, 7].
Several cases of transfusion transmission of B19V have been re-
ported, and many B19V-contaminated blood donations have been 
retrospectively or prospectively detected. B19V transfusion-trans-
mitted infections (TTI), however, seem to be quite rare with RBCs 
and platelet concentrates (PCs) [4, 5, 8–10]. Apart from the com-
mon asymptomatic course of the disease and the fact that the infec-
tion is often not well recognised by many physicians, the most 
probable reason for the relatively few B19V TTIs is the presence of 
neutralising anti-B19V antibodies stemming either from the dona-
tion itself or being already present in the recipient [4]. The rela-
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Summary
Background: Pathogen reduction methods for blood 
components are effective for a large number of viruses 
though less against small, non-enveloped viruses such 
as Parvovirus B19 (B19V). This article describes the pas-
sive transmission by transfusion of two B19V-contami-
nated pooled platelet concentrates (PCs) which were 
treated with the Intercept® blood pathogen reduction 
system. Case Reports: Two transfusion cases of B19V-
contaminated Intercept-treated pooled PCs were de-
scribed. Due to the analysis delay, the PCs were already 
transfused. The viral content of each donation was 4.87 × 
1010 IU/ml in case 1and 1.46 × 108 IU/ml in case 2. B19V 
(52 IU/ml) was detected in the recipient of the case 1 PC, 
whereas no virus could be detected in the case 2 PC re-
cipient. A B19V IgM response and a transient boost of 
the underlying B19V IgG immune status and was ob-
served in recipient 1. Recipient of the case 2 PC remained 
B19V IgG- and IgM-negative. B19V DNA sequence and 
phylogenetic analysis revealed a 100% homology be-
tween donor and recipient. Conclusion: This report de-
scribes passive B19V transmission by a PC with very 
high B19 viral load which elicited a transient boost of the 
B19V immunity, but not by a PC with a lower B19V con-
tent, suggesting that there is a B19 viral load threshold 
value at which B19V inactivation is exceeded.
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tively common B19V contamination of plasma derivatives led to 
widespread adoption of B19V nucleic acid testing (NAT) screening 
of source and recovered plasma donations to detect high-titre vi-
raemic units before pooling and fractionation in the pharmaceuti-
cal industry [2, 11–13].
As in many European countries, NAT of blood donors for B19V 
is not mandatory for the release of labile blood products in Switzer-
land but is routinely performed by the manufacturer of fractiona-
tion plasma [2]. Since 2007, all donations at the Interregional 
Blood Transfusion SRC Ltd (formerly Blood Transfusion Service 
(BTS) SRC Berne) were tested for B19V by NAT with a sensitivity 
limit of 106 IU/ml in the individual donation. Plasma derivatives 
that exceed this limit are excluded from the manufacturing plasma 
pools. Because this test is performed after the release of the labile 
products, stored infectious units are discarded by post-donation 
information procedures. Those units already transfused are traced 
by a look-back procedure.
Pathogen reduction methods for blood components have been 
shown to be effective for a large number of pathogens including 
B19V [14, 15]. In 2011, Switzerland was the first country introduc-
ing nation-wide the pathogen reduction of PCs with amotosalen 
and UVA (Intercept® blood pathogen reduction system; Cerus 
Corporation, Amersfoort, Netherlands ) [16]. The degree of B19V 
reduction achieved has been reported to range from 3.5 to 5 log of 
B19V by the infectivity assay or up to reach 6 logs as measured by 
polymerase chain reaction (PCR) inhibition [14, 15, 17].
Material and Methods
NAT screening for B19V is performed in pools of up to 480 donations on a 
twice weekly basis. The validated in-house quantitative NAT for B19V DNA for 
all 3 known genotypes has a 95% sensitivity limit in an individual donation of 
32.7 IU/ml (95% CI 27.1–42.8 IU/ml). B19V-positive pool samples containing 
>1 × 104 IU/ml B19V DNA are resolved to the single donation. Those dona-
tions with viral loads >1 × 106 IU/ml B19V DNA are removed from the plasma 
fractionation process. The corresponding RBCs and PCs are also removed from 
the stock by post-donation information procedure. Already transfused PCs are 
traced by a look-back procedure in the patients. Our laboratory adheres strictly 
to precautionary measures to prevent sample contamination. Sample prepara-
tion, reagent preparation and amplification are strictly separated in different 
laboratories. Pooled PCs are manufactured by the buffy coat method out of 5 
whole blood donations and routinely treated with amotosalen and UVA (Inter-
cept blood pathogen reduction system) [18]. From the 5 pooled buffy coats 
there remains 125–130 ml of the original plasma in the final pathogen-reduced 
PC, thus from each involved donation approximately 25 ml rest plasma remains 
in the final product.
B19V ELISA and Immunoblot serology (IgG and IgM) was performed with 
commercial assays (DiaSorin Ireland Ltd., Dublin, Irland; MIKROGEN GmbH, 
Neuried, Germany). Epitope specificity of the IgG antibodies and avidity was 
investigated using the Immunoblot. B19V DNA sequence analysis was per-
formed on a partial coding NS1/VP1 unique 936 bp PCR fragment of the B19V 
genome and were aligned using CLUSAL_W [19, 20]. Phylogenetic and molec-
ular evolutionary analyses were conducted with MEGA version 6 using the 
nearest-neighbour joining method from a Kimura 2-parameter distance matrix 
[21].
Case Reports
B19V NAT is conducted in pools of up to 480 donations twice weekly, and 
positive pools are resolved to the single donation with further B19V NAT anal-
yses. The delay in detecting the corresponding B19V-contaminated blood unit 
is approximately 5 days. Since B19V NAT is not mandatory for the release of 
labile blood products, including PCs, occasionally these products are transfused 
before a recall of the product is initiated. Here we report two cases of suspected 
transfusion-transmitted B19V transmissions.
Case 1
A 74-year-old female patient was transfused with a pooled PC which con-
tained a PC from a B19V NAT-positive donation. The viral load of the B19V-
contaminated donation was 4.87 × 1010 IU/ml. The donor, a 37-year-old repeat 
male donor, was unaware of his active B19V infection. Ten days post transfusion 
a B19V viral load of 52 IU/ml was measured in the plasma of the recipient as part 
of a look-back investigation. B19V DNA sequence and phylogenetic analysis of 
the partial NS1/VP1 unique 936 bp PCR fragment revealed a B19V genotype 1a 
for both viruses and a 100% homology between the B19V isolate from the donor 
and recipient (fig.  1). After 74 days B19V was undetectable in the recipient’s 
blood. B19V IgG and IgM serology were conducted for the donor and patient’s 
blood samples which were available. The original B19V-contaminated donation 
was both B19V IgG- and IgM-negative but the donor was strongly positive for 
B19V IgG and IgM at 52 days post donation, indicating a very recent B19V infec-
tion. Unfortunately no plasma sample was available from the recipient prior to or 
during the PC transfusion. At 10 days post transfusion the B19V IgG test was 
positive up to 1: 1,000, whereas after 74 days a positive B19V IgG value was meas-
ured up to 1: 100, suggesting a transient boost of an underlying B19V IgG im-
mune status. Immunoblot analysis on both post-transfusion samples revealed 
IgG antibodies to the minor and major capsid antigens (VP1/2) as well as to the 
non-structural protein NS1, and the avidity was high, further suggesting a previ-
ous B19V immunity. B19V IgM antibodies were detected in an Immunoblot on 
the 10-day post-transfusion sample, but not in the follow-up sample. 
Case 2
A 72-year-old male patient was transfused with a pooled PC which con-
tained a PC from a B19V NAT-positive donation. The viral load of this con-
taminated donation was 1.46 × 108 IU/ml. The donor, a 41-year-old repeat male 
donor, was unaware of his active B19V infection, and no B19V IgG or IgM anti-
bodies were detected in the B19V-contaminated donation. At 52 days post do-
nation the donor had, as expected, seroconverted for B19V antibodies (both 
B19V IgM and IgG >1: 10 positive). In a look-back investigation, no evidence 
for B19V transmission from donor to recipient either by NAT or IgG or IgM 
serology was detected at 4 and 9 days post transfusion. Unfortunately no later 
samples were available.
Discussion
Pathogen reduction methods for blood components (including 
Intercept) are effective for a large number of viruses; however, it has 
been reported that they are more efficient against enveloped viruses 
than against small, non-enveloped viruses such as B19V and hepati-
tis E virus (HEV). We are not aware of any other case reports of 
B19V transmission after amotosalen and UVA treatment. There was 
a recent report of a HEV TTI after Intercept blood system treatment; 
HEV is a non-enveloped icosahedral virus similar to B19V but with 
a RNA rather than DNA genome [22]. Here we describe 2 cases of 
B19V-contaminated pooled PCs which were treated with Intercept 
blood system and transfused to two recipients before the contamina-
tion was detected and the products could be removed from the 
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transfusion process. The B19V viral burden of the original dona-
tions differed by approximately 2.5 logs (4.87 × 1010 IU/ml vs. 1.46 × 
108 IU/ml). A B19V transmission (52 IU/ml in recipient 1, 10 days 
post transfusion) was documented for the donation with the high 
B19V viral load (>4.87 × 1010 IU/ml) and confirmed by identical se-
quences identified in donor and patient. No transmission was de-
tected, however, in case of the PC produced from the donation con-
taminated with 1.46 × 108 IU/ml B19V, suggesting that there is a 
B19V viral load ‘threshold value’ at which pathogen inactivation is 
exceeded. The data presented in case 1 is consistent with a passive 
transmission of B19V to a B19V seropositive patient which has 
caused a reactivation of the immune response. An infection may 
have transiently occurred; however, due to the patient’s presumed 
seropositivity and likely B19V IgG antibodies from the other donors 
in the pooled PC a transmission, but not an infection, is the most 
likely explanation. Further serological B19V assays (IgM and IgG 
Immunoblot) on the samples available revealed a B19V IgM re-
sponse in the sample 4 days after transfusion and a high avidity in 
the B19V IgG response; both results are consistent with a B19V 
transmission to a seropositive individual.
Asymptomatic B19V primary infected individuals often present 
with extremely high viral burden of 108 to 1014 IU/ml which are 
often identified in unsuspected blood donors [7, 23]. Our routine 
B19V NAT screen of pooled blood donations (up to 480 donations) 
identifies those pools harbouring a B19V viral load >1.00 × 104 IU/
ml to be resolved to the single positive donation. From 2008 to 2015, 
973,796 blood donations were screened. 68 donations were identi-
fied with a viral burden >1.00 × 106 IU/ml (0.007% of the total dona-
tions tested) after resolving the pools to the single donation. Similar 
levels of B19V DNA-positive donations have been reported in other 
middle European countries (The Netherlands: 0.006% >1.00 × 106 
IU/ml and Germany/Austria: 0.0018% >1.00 × 105 IU/ml) [24, 25]. 
Interestingly nearly 40% of the B19V-positive samples harboured 
high B19V burdens (26 donations, >1.00 × 1010 IU/ml, 0.003% do-
nations tested), similar to the donation implicated in case 1 (4.87 × 
1010 IU/ml). Such very high B19V DNA-positive blood levels occur 
during the short highly viraemic phase after primary infection be-
fore the B19V IgM and IgG immune response starts around 10 days 
after infection [2, 7]. In both cases described, the plasma of the 
B19V-contaminated donation was devoid of both B19V-specific 
IgM and IgG antibodies. Unfortunately, the B19V anti-IgG and 
-IgM status of the 8 other donors involved in the pooled platelet 
concentrates could not be determined as no sample was available. 
However, since the seroprevalence of B19V IgG antibodies in adults 
is known to be high (>60% at 20 years up to >75% at 65 years), it is 
highly likely that both concentrates contain at least one seropositive 
donor and thus similar levels of neutralising antibodies [26]. Differ-
ences in the levels of B19V IgG antibodies in the two PCs may have 
played a role in the outcome of the two cases; however, the distinct 
difference between the rest viral concentrations is in our opinion the 
major distinction and therefore the probable essential difference.
Amotosalen and UVA treatment is clearly an effective proce-
dure to inactivate or reduce viral, bacterial and parasitic contami-
nation of platelets and (in the future) other blood components [14, 
15]. Due to its often extremely high B19V blood concentrations 
and the reported less effectively of the amotosalen and UVA treat-
ment against the tightly formed protein B19V capsids, the potential 
for a B19V transmission and perhaps infection from B19V-con-
taminated blood products has not been eliminated. The PCR inhi-
bition assay reported by Sawyer and colleagues [17] demonstrated 
Fig. 1. Case 1. Donor/
recipient B19V phyloge-
netic analysis of a par-
tial NS1-VP1 unique 
 region against known 
B19V genotype se-
quences. Nearest-neigh-
bour method from a 
Kimura 2-parameter 
distance matrix.
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a 6-log inactivation of full-length B19V DNA templates, but only a 
2-log inhibition of 1kb templates. There thus appears to be enough 
adducts to inactivate 106 IU of B19V. In case 1, the contaminated 
pooled PC transfused contained 1.22 × 1012 IU of B19V prior to 
Intercept treatment. Even a 6-log reduction would leave a substan-
tial number of virus particles without adducts and thus potentially 
infectious. In case 2 the viral load was >2 logs lower than in case 1, 
and thus less viral particles were potentially free from adducts after 
Intercept treatment.
B19V infectivity reduction after treatment with the Intercept 
blood system has been reported to range between 3.5 and 5 logs 
[14, 15]. After Intercept treatment of the transfused PCs produced 
from the pooled buffy coats, there still remains 125–130 ml of the 
original plasma or about 25 ml from each donation of a pool of 5 
donations. Extrapolated from these calculations it can be assumed 
that in the first case 1.22 × 1012 IU of B19V were treated with Inter-
cept blood system (table 1) and thus between 1.22 × 107 and 3.85 × 
108 IU remained in the PC, depending on the expected range of 
pathogen reduction, and this was transfused to the recipient. Thus 
the presumed underlying B19V immunity was not sufficient to 
neutralise and eliminate the passive transfer of the virus after 10 
days, or perhaps the virus was able to transiently infect the recipi-
ent and produce new virus. This observation was consistent with 
B19V IgG increases after transfusion of two B19V IgG-positive 
volunteers with 200 ml of PLAS+SD at a DNA concentration of 1.6 
× 108 IU/ml [5] as well as with a further report of a four-fold boost 
in the B19V IgG in a follow-up sample from a recipient of a blood 
component with a very high B19V content (approximately 5.8 × 
1011 IU B19V DNA) [27].
This report brings up several points which need to be addressed 
by the blood transfusion community in the future. High-titre B19V 
blood donations are often detected by blood transfusion services 
especially during the periodic waves of infection which are known 
to occur. The current use of pathogen reduction technologies has 
certainly been successful in reducing the risk of viral transmission 
via transfusion. However, it does have limitations with regard to 
high titre non-enveloped viruses as highlighted in the present re-
port and is at present only used routinely for PCs. B19V NAT is at 
present not required for the release of blood products, and in addi-
tion only those donations with >106 IU/ml are identified. In the 
future it is not prudent to suggest for high-risk patients (i.e. preg-
nant women and immunocompromised patients) a selection of 
blood products which have been screened with single-unit NAT 
for B19V and perhaps other non-enveloped viruses. Alternatively 
B19V NAT could be declared mandatory for the release of all blood 
products with the already known consequences. This in turn poses 
the pertinent question whether national health services are pre-
pared to bear the extra cost this will bring about.
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Table 1. Case studies: B19V burden estimations after pathogen reduction under 2 different assumptions: log reduction of the viral burden of 5 and 3.5a
Range log reduction B19V after reduction, IU/ml B19V in 25ml rest plasma in PC  
before reduction, IU
B19V in 25ml rest plasma in PC  
after reduction, IU 
Case 1 (B19V burden: 4.87 × 1010)
5 log 4.87 × 105 1.22 × 1012 1.22 × 107 
3.5 log 1.54 × 107 1.22 × 1012 3.85 × 108 
Case 2 (B19V burden: 1.46 × 108)
5 log 1.46 × 103 3.65 × 109 3.65 × 104 
3.5 log 4.62 × 104 3.65 × 109 1.15 × 106 
aThe range of B19V reduction is reported to range from 3.5–5 log [12, 13].
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